Literature DB >> 1652617

Detection of genital human papillomaviruses by polymerase chain reaction amplification with degenerate nested primers.

A L Williamson1, E P Rybicki.   

Abstract

Degenerate oligonucleotide primers were designed for in vitro amplification by polymerase chain reaction (PCR) of a relatively well-conserved portion of the L1 capsid protein gene of genital human papillomaviruses. A specific 441bp fragment was amplified by PCR from genomic clones and clinical biopsy specimens containing DNA from HPV types 6, 11, 16, 18, 31, and 33, as well as from a number of other clinical specimens known to contain unclassified HPV isolates. As some HPV non-specific DNA was also often amplified, another set of degenerate primers was designed which amplified a 335 bp sequence contained within the 441 bp sequence. These nested primers could be used in a two-stage PCR reaction to obtain distinct HPV-specific DNA fragments suitable for direct sequencing. Two-stage PCR was used to demonstrate the presence of HPV DNA in 13 out of 16 biopsies, which had been classified histologically as cervical intraepithelial neoplasia (CIN), but which were negative for HPV on Southern blot hybridization. Seven of these amplification products were sequenced, and one proved to be a previously unsequenced HPV type. The results have important implications for the routine detection and typing of genital and other HPV types in clinical samples.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1652617     DOI: 10.1002/jmv.1890330305

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  10 in total

1.  From plant virology to vaccinology: The road less travelled.

Authors:  Edward Rybicki
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

2.  New nucleotide sequence data on the EMBL File Server.

Authors: 
Journal:  Nucleic Acids Res       Date:  1991-09-25       Impact factor: 16.971

3.  Identification of six putative novel human papillomaviruses (HPV) and characterization of candidate HPV type 87.

Authors:  S Menzo; A Monachetti; C Trozzi; A Ciavattini; G Carloni; P E Varaldo; M Clementi
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

4.  Seropositivity against HPV 16 capsids: a better marker of past sexual behaviour than presence of HPV DNA.

Authors:  A O Olsen; J Dillner; K Gjøen; P Magnus
Journal:  Genitourin Med       Date:  1997-04

5.  A deletion polymorphism in the human alpha-2-macroglobulin (A2M) gene.

Authors:  G Matthijs; P Marynen
Journal:  Nucleic Acids Res       Date:  1991-09-25       Impact factor: 16.971

6.  Detection of human papillomavirus in vulval carcinoma using semi-nested PCR and restriction enzyme typing: a rapid and sensitive technique.

Authors:  N H Cartwright; L J Cassia; A J Easton; A G Morris
Journal:  Clin Mol Pathol       Date:  1996-08

7.  Sequence variation in the L1 gene of human papillomavirus type 16 from Africa.

Authors:  J E Ramesar; E P Rybicki; A L Williamson
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

8.  Comparison of a one-step and a two-step polymerase chain reaction with degenerate general primers in a population-based study of human papillomavirus infection in young Swedish women.

Authors:  M Evander; K Edlund; E Bodén; A Gustafsson; M Jonsson; R Karlsson; E Rylander; G Wadell
Journal:  J Clin Microbiol       Date:  1992-04       Impact factor: 5.948

9.  Group-specific differentiation between high- and low-risk human papillomavirus genotypes by general primer-mediated PCR and two cocktails of oligonucleotide probes.

Authors:  M V Jacobs; A M de Roda Husman; A J van den Brule; P J Snijders; C J Meijer; J M Walboomers
Journal:  J Clin Microbiol       Date:  1995-04       Impact factor: 5.948

10.  More men than women make mucosal IgA antibodies to Human papillomavirus type 16 (HPV-16) and HPV-18: a study of oral HPV and oral HPV antibodies in a normal healthy population.

Authors:  Dianne J Marais; Candice Sampson; Anthea Jeftha; Dherendra Dhaya; Jo-Ann S Passmore; Lynette Denny; Edward P Rybicki; Eric Van Der Walt; Lawrence Xg Stephen; Anna-Lise Williamson
Journal:  BMC Infect Dis       Date:  2006-06-08       Impact factor: 3.090

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.